Lu-PSMA-617 cuts prostate cancer progression 28%, interim

Editor's Pick: [Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial (The Lancet, 2026)
Welcome to This Week in Oncology. This week we're covering 9 notable papers spanning treatment intensification in advanced solid tumours, biomarker-guided and antibody-drug conjugate strategies, and the growing evidence base for supportive care and long-term survivorship. Let's dive in.

We start with intensification of first-line therapy, and the headline trial comes from The Lancet.
This week's papers:
• [Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial — The Lancet 2026 (pubmed.ncbi.nlm.nih.gov/42561994)
• Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial — JAMA 2026 (pubmed.ncbi.nlm.nih.gov/42574006)
• Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42579833)
• SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42562209)
• Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648 — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42575473)
• Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42560727)
• Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low HER2 Expression — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42579830)
• Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2 — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42561216)
• Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42566728)
Listen at AudioScholar (audioscholar.cc/episode/dtsrweq9u3)